Skip to main content
BSTCinactive

BIOSPECIFICS TECHNOLOGIES CORP

Biopharma developer (SEC filing verified)·Phase 1·CEO: Joseph Truitt Interim
OncologyReproductive

BSTC evidence brief

What we can confirm

BioSniper Score:
3.7 / 10
Lead Asset:
xiaflex (Phase 1)

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

BioSniper Score: 3.7 / 10 · Lead Asset: xiaflex (Phase 1)
BioSniper AIPage evidence connected

Prepared research question

What matters most for BSTC—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

3.7/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

—

Cash Runway

—

Lead Asset

xiaflex (Phase 1)

Next Catalyst

—

Tracking 1 pipeline candidate for BIOSPECIFICS TECHNOLOGIES CORP.

Similar companies

PROF

Run BIOSPECIFICS TECHNOLOGIES CORP through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available BIOSPECIFICS TECHNOLOGIES CORP facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 2 of 6 signals · derived from public data

Cash RunwayN/A

Cash runway data unavailable

Financial HealthN/A

Financial health data unavailable

Pipeline Maturity4.0

Lead: Phase 1

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Pipeline

Run my thesis on this company

Governance

Run my thesis on this company

Frequently asked questions

What is BIOSPECIFICS TECHNOLOGIES CORP's lead drug candidate?

BIOSPECIFICS TECHNOLOGIES CORP's most advanced tracked candidate is xiaflex (Phase 1) for Uterine fibroids.

Who is the CEO of BIOSPECIFICS TECHNOLOGIES CORP?

Joseph Truitt Interim is the chief executive officer of BIOSPECIFICS TECHNOLOGIES CORP (BSTC).

What therapeutic areas does BIOSPECIFICS TECHNOLOGIES CORP focus on?

BIOSPECIFICS TECHNOLOGIES CORP develops therapies across Oncology, Reproductive.

923 companies304,846 SEC filings22,651 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.